I agree. Here's the catch 22 - had we partnered with a big...

I agree. Here's the catch 22 - had we partnered with a big pharma, we would get the publicity but likely get screwed on the deal. This way, we don't get the publicity (until it really matters) and we negotiate favourable financial and commercial terms.

I think the only way we'll now get the publicity we need is if we move into another indication. Tom said today that they have enough money to conduct a P3 trial (x1) and enough financial flexibility to look at another indications. That was a key point for me. It seems they are also aware of the need to branch out. This partnership can facilitate that. Peptron has developed a sustained-release version of Exenatide ((SR)-Exenatide) to investigate its neuroprotective effects in Parkinson's disease (https://clinicaltrials.gov/ct2/show/NCT04269642).